
    
      This is an open-label (all people know the identity of the intervention), multicenter, phase
      2 study to evaluate the clinical efficacy, safety and pharmacokinetics of erdafitinib in
      Asian participants with advanced NSCLC, urothelial cancer, esophageal cancer and
      cholangiocarcinoma.
    
  